Pharmacy Medical News about Rituximab;immunotherapy;Mituprotimut-T;follicular lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
Journal of Clinical Oncology, 06/22/09

Freedman A et al. - Study demonstrates that time to progression (TTP) was shorter with mitumprotimut-T/GM-CSF compared with placebo/GM-CSF in patients with CD20+ follicular lymphoma. This difference was possibly due to the imbalance in Follicular Lymphoma International Prognostic Index (FLIPI) scores.

Methods

Aim was to evaluate patient-specific immunotherapy with mitumprotimut-T and GM-CSF in CD20+ follicular lymphoma
Patients: treatment-naive or relapsed/refractory disease achieving a CR, PR, or SD with 4 weekly rituximab infusions
Pts randomly assigned to mitumprotimut-T/GM-CSF or placebo/GM-CSF
Doses: monthly for 6 doses, every 2 mo for 6 doses, and then every 3 mo until disease progression (PD)
Randomization was stratified by prior therapy and response to rituximab
Primary end point: TTP from randomization

Results

349 pts; median age: 54 yrs; 79% were treatment naive, and 86% had stage III/IV disease
Median TTP was 9.0 mo for mitumprotimut-T/GM-CSF and 12.6 mo for placebo/GM-CSF
TTP was comparable between the 2 arms in treatment-naive pts and shorter with mitumprotimut-T/GM-CSF in relapsed/refractory disease
After adjusting for FLIPI scores, the difference in TTP between the 2 arms was no longer significant
Overall objective response rate, rate of response improvement, and duration of response were comparable between the 2 arms
Toxicity was similar in the 2 arms:
- 76% of adverse events were mild or moderate, and
- 94% of patients had injection site reactions

<< Previous
Cannabinoid receptor type 2 activation induces a microglial...

Next >>
Gatekeeping versus direct-access when patient information matters